KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to -$93.7 million.

  • Arbutus Biopharma's Enterprise Value rose 2667.73% to -$93.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$93.7 million, marking a year-over-year increase of 2667.73%. This contributed to the annual value of -$122.6 million for FY2024, which is 268.25% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Enterprise Value of -$93.7 million as of Q3 2025, which was up 2667.73% from -$98.1 million recorded in Q2 2025.
  • Arbutus Biopharma's 5-year Enterprise Value high stood at -$78.4 million for Q2 2021, and its period low was -$165.5 million during Q1 2022.
  • Moreover, its 5-year median value for Enterprise Value was -$132.0 million (2021), whereas its average is -$130.0 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first crashed by 39954.95% in 2021, then soared by 3091.71% in 2025.
  • Over the past 5 years, Arbutus Biopharma's Enterprise Value (Quarter) stood at -$155.3 million in 2021, then increased by 5.41% to -$146.9 million in 2022, then grew by 14.23% to -$126.0 million in 2023, then rose by 2.68% to -$122.6 million in 2024, then rose by 23.59% to -$93.7 million in 2025.
  • Its Enterprise Value was -$93.7 million in Q3 2025, compared to -$98.1 million in Q2 2025 and -$112.7 million in Q1 2025.